Across its top 20 institutional holders, ALDX's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 9/100, avg. turnover score 41/100).

Quarterly Activity

Recent Activity

+$28.1M

Total Buy Value

$110.9M

Total Sell Value

New buy17

Trim38

Add51

Sold out31

Net Buyers

Net Sellers

Smart Money Convergence

ALDX does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.

13F data as of 2026-06-30 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

Filings (14d)

Data as of 2026-07-15

2026-07-15

Aldeyra Therapeutics received minutes from a Type A meeting with the FDA regarding the potential resubmission of its new drug application for reproxalap, a treatment for dry eye disease. The company requested clarification of those minutes and plans to request a Type D meeting, expected by the end of Q3 2026, to discuss resubmission.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

CUSIP

01438T106

FAQ

Who are the top institutional investors holding ALDEYRA THERAPEUTICS INC (ALDX)?

Major stakeholders currently include Knoll Capital Management, LLC ($9.3M), BlackRock, Inc. ($6.4M), Aqr Capital Management LLC ($4.8M). Based on the latest 13F filings, there are a total of 125 tracked investment funds and institutions maintaining positions in ALDX.

What is the overall institutional sentiment toward ALDX recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $139.8M, driven by 68 managers accumulating shares while 69 reduced their exposure.

Which institutions have been selling or reducing their ALDX positions?

In the latest period, 38 funds trimmed their holdings, and 31 managers completely exited their positions. The aggregate reported sell value was $110.9M.

Are there any notable investors adding ALDX to their portfolios?

Yes, buying activity remains notable. 17 institutions opened new positions in {ticker}, and 51 existing holders added to their shares. The total reported buy value for the quarter amounted to $28.1M.